Assess Safety and PK of ADASUVE® in Children and Adolescents Using an Antipsychotic Medication

Study Title

Study to Assess the Safety and Pharmacokinetics of ADASUVEֲ® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

Teva Identifier

TV571-CNS-10018

ClinicalTrials.gov Identifier

NCT02184767

Study Status

Completed

Trial Condition(s)

BiPolar

Interventions

Drug: ADASUVEֲ®

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender

Female, Male

Age Range

10 Years to 17 Years

Trial Duration

07/01/2014 - 05/01/2015

Phase

Phase 1

Study Type

Interventional